James F Blake

USPTO Granted Patents = 112 (Patent Applications = 36)

CIPO Patents = 21 (Patent Applications = 9)

EPO Patents = 36 (Patent Applications = 42)

Average Co-Inventor Count = 8.2

ph-index = 13

Forward Citations = 637(Granted Patents)

Inventors with similar research interests:

Location History:

Boudler, CO (US) (2018)
Longmont, CO (US) (2007 - 2024)
Boulder, CO (US) (2012 - 2024)
Indianapolis, IN (US) (2024)

Company Filing History:

Mirati Therapeutics, Inc.

Vertex Pharmaceuticals, Inc.

Eli Lilly and Company

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

112 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12351571 - Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases (2025-07-08),

2. 12187721 - Protein tyrosine phosphatase inhibitors (2025-01-07),

3. 12180207 - Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases (2024-12-31),

4. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),

5. 11964989 - KRas G12D inhibitors (2024-04-23),

6. 11964988 - Fused heterocyclic compounds as RET kinase inhibitors (2024-04-23),

7. 11932633 - KRas G12C inhibitors (2024-03-19),

8. 11884664 - Protein tyrosine phosphatase inhibitors (2024-01-30),

9. 11851434 - Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors (2023-12-26),

10. 11802127 - 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors (2023-10-31),

11. 11691973 - 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors (2023-07-04),

12. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2023-05-16),

13. 11634417 - Protein tyrosine phosphatase inhibitors (2023-04-25),

14. 11603374 - Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors (2023-03-14),

15. 11524963 - Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors (2022-12-13),

Title: Innovative Patents by James F Blake: Ret Kinase and Protein Tyrosine Phosphatase Inhibitors

Introduction:

In the fast-paced world of pharmaceutical research and development, inventors like James F Blake play a pivotal role in advancing medical science. With his location in Boulder, CO (US), Blake has made significant contributions with an impressive portfolio of 101 patents. This article will highlight some of his groundbreaking inventions, including his latest discoveries in the field of substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors and protein tyrosine phosphatase inhibitors.

Ret Kinase Inhibitors - Treating RET-Associated Diseases:

James F Blake's notable patents include the development of substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors. These compounds are indispensable in the treatment and prevention of diseases that can be effectively addressed using a RET kinase inhibitor, particularly RET-associated diseases and disorders.

By targeting RET kinases, which are known to contribute to the development of several malignant tumors and other debilitating health conditions, Blake's invention represents a significant breakthrough in personalized medicine.

Protein Tyrosine Phosphatase Inhibitors - Inhibiting Hyperproliferative Diseases:

In addition to RET kinase inhibitors, James F Blake has also made significant contributions to the field of protein tyrosine phosphatase inhibitors. These inhibitors, as disclosed in his patents, are vital in the treatment of hyperproliferative diseases.

The compounds he has developed (Formula I) have shown promise in inhibiting the abnormal cellular growth typically associated with these diseases. Moreover, the patents also describe various methods of diagnosing, preventing, and treating hyperproliferative conditions in mammalian cells, paving the way for potential therapeutic innovations.

Collaborative Efforts and Industry Involvement:

Throughout his career, James F Blake has worked with esteemed companies at the forefront of medical research. Notable mentions include Array BioPharma Inc. and Covenantech, Inc. These research-driven organizations have provided him with a platform to contribute his expertise towards groundbreaking pharmaceutical developments.

Working alongside talented colleagues such as Gabrielle R Kolakowski and Steven Wade Andrews has clearly been instrumental in Blake's success, as collaborative efforts often lead to accelerated knowledge exchange and innovative outcomes.

Conclusion:

James F Blake is a trailblazer in the field of pharmaceutical research and development, with a remarkable portfolio of 101 patents. His most recent inventions concerning substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors and protein tyrosine phosphatase inhibitors are poised to revolutionize disease treatment and prevention.

Through his collaborations with industry-leading companies like Array BioPharma Inc. and Covenantech, Inc., Blake's contributions to medical science continue to impact global healthcare. As we eagerly await future breakthroughs, it is clear that James F Blake's dedication to innovation and pushing boundaries will leave a lasting legacy in the field of pharmaceutical innovation.

This text is generated by artificial intelligence and may not be accurate.